Last reviewed · How we verify

Aggrastat — Competitive Intelligence Brief

Aggrastat (TIROFIBAN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platelet Aggregation Inhibitor. Area: Cardiovascular.

marketed Platelet Aggregation Inhibitor Integrin alpha-IIb/beta-3 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aggrastat (TIROFIBAN) — Medicure. Aggrastat works by blocking the integrin alpha-IIb/beta-3 receptor on platelets, preventing them from aggregating and forming blood clots.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aggrastat TARGET TIROFIBAN Medicure marketed Platelet Aggregation Inhibitor Integrin alpha-IIb/beta-3 1998-01-01
Integrilin EPTIFIBATIDE Merck & Co. marketed Platelet Aggregation Inhibitor [EPC] Integrin alpha-IIb/beta-3 1998-01-01
Reopro ABCIXIMAB Johnson & Johnson marketed Integrin alpha-IIb/beta-3 1993-01-01
Persantine DIPYRIDAMOLE Boehringer Ingelheim marketed Platelet Aggregation Inhibitor [EPC] Equilibrative nucleoside transporter 1 1961-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platelet Aggregation Inhibitor class)

  1. Medicure · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aggrastat — Competitive Intelligence Brief. https://druglandscape.com/ci/tirofiban. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: